By combining their complementary strengths, the two companies are creating a more localized and competitive platform to develop innovative products, enhance operational efficiency and support long-term sustainable growth.

CHARLOTTE, N.C., Oct. 2, 2026 /PRNewswire/ — Midea Group and Electrolux Group are advancing their long-term strategic partnership in North America as all three joint ventures are now live. This milestone brings together two global industry leaders with a shared ambition: to strengthen product competitiveness, accelerate innovation and deliver even greater value to consumers and customers.

The partnership was announced on April 23, 2026, building on more than 20 years of collaboration. It brings together the companies’ capabilities in manufacturing, product development, innovation, supply chain and commercial strategies to deliver stronger value to customers and consumers in North America.

“As all three joint ventures go live, the partnership marks a concrete step forward in the companies’ long-term strategy in North America. By bringing our strengths together and working more closely across product development, operations and go-to-market, we can convert years of collaboration into new opportunities to innovate, improve efficiency and better serve consumers and customers,” said Louis Zhao, Vice President of Midea Group & President of Smart Home Business Group.

“This partnership marks a major milestone in the execution of Electrolux Group’s strategy and puts us in a position to accelerate profitable growth. It enables us to continue to invest in sustainable, consumer-centric innovations to serve our customers and consumers with even stronger product offerings in North America,” said Yannick Fierling, President & CEO of Electrolux Group.

Looking ahead, Midea Group and Electrolux Group will continue strengthening local manufacturing and supply capabilities to meet evolving consumer needs. Together, the companies plan to achieve annual North American production of Food Preservation and Fabric Care products that is roughly double current capacity, while also expanding into new product categories.

About Midea Group

Midea is a global technology group covering seven business segments, including smart home, industrial technology, building technologies, robotics and automation, energy, healthcare, as well as smart logistics.  Founded in 1968, Midea serves over 500 million users annually and operates more than 400 subsidiaries, 41 R&D centers and 68 major production bases across more than 200 countries and regions. The group has invested over USD 10.4 billion in R&D over the past five years.

About Electrolux Group

Electrolux Group is a leading global appliance company that has been shaping living for the better for more than 100 years. Through leading brands including Electrolux, AEG and Frigidaire, the group delivers solutions across taste, care and well-being to consumers in around 120 markets, with sustainability at the heart of its products and operations. In 2025, Electrolux Group recorded sales of 131 billion Swedish kronor and employed approximately 39,000 people worldwide.

DALLAS, Oct. 2, 2026 /PRNewswire/ — Sekisui Specialty Chemicals announced today that it will increase the price of Selvol^® Polyvinyl Alcohol, Selvol Ultiloc^®, Selvol Ultalux^®, and Selvol Premiol^® products up to the amounts shown in the table.

Sekisui Specialty Chemicals remains committed to meeting customers’ needs with high quality products. The increase will take effect on October 15^th, 2026, or as contracts and agreements allow. Customers should contact their local Sekisui sales representative for more details.

Sekisui Specialty Chemicals’ primary product is Selvol, a line of high-performance polyvinyl alcohol polymers and copolymers used in paper, adhesive, packaging, construction, personal care, and many other specialty formulations. Selvol Ultiloc copolymers are Sekisui’s most recent innovation, bringing new functionality to the long trusted Selvol product line. The company also represents Advancell expandable microspheres and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion-dollar, global company that delivers a wide range of products and services to enrich people’s lives. The company is comprised of core businesses and technologies in housing, social infrastructure, and chemical solutions. For more information, visit www.sekisui-sc.com/

PALO ALTO, Calif., Oct. 2, 2026 /PRNewswire/ — I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPS cell) technologies for regenerative medicine and longevity, today announced that it was selected as one of the awardees for the Top 10 Longevity Breakthrough Awards at the 2026 Asia-Pacific Healthy Longevity International Summit. The award was presented for I Peace’s research and development of iPSF, a cell-free product derived from culture supernatant of iPS cells.

“We are honored to be recognized as one of this year’s Top 10 Longevity Breakthrough award recipients,” said Dr. Koji Tanabe, Founder and CEO of I Peace, Inc. “This recognition reflects our team’s commitment to advancing the possibilities of iPS cell technology and exploring new approaches in the longevity field. We are proud to be included among such respected innovators and look forward to continuing our efforts to progress iPSC science.”

The Longevity Breakthrough Awards recognizes innovative technologies and research with the potential to contribute to healthy longevity, based on scientific and medical evidence.

A Cell-Free Technology Focused on Components Derived from iPS Cells

Research and development in regenerative medicine using iPS cells is advancing worldwide, with clinical trials currently underway across multiple disease areas. Findings from these studies suggest that the therapeutic effects of iPSC-derived cells may arise not only from the engraftment and replacement of damaged tissues, but also from various bioactive factors released by these cells that influence surrounding cells and tissues.

Focusing on these intercellular signaling mechanisms, I Peace has been developing iPSF as a cell-free technology that utilizes components derived from iPSC-derived cells, rather than administering the cells themselves.

Researching Potential Applications for Age-Related Cellular and Tissue Changes

iPSF is obtained by isolating and purifying factors produced during the culture supernatant of iPSC-derived cells. Research conducted to date has observed changes related to extracellular matrix production and aging-associated biomarkers. I Peace is currently investigating the underlying mechanisms of action, as well as the safety and potential utility of iPSF.

In addition, the company is conducting foundational research and exploratory evaluations into potential applications for various tissues whose function may decline with age, including skin and hair. Going forward, I Peace plans to carefully assess reproducibility, safety, and clinical relevance through appropriately designed studies.

Bringing iPS Cell Technology to the Longevity Field

In recent years, research and development in longevity medicine has expanded rapidly worldwide, with scientists seeking to understand the biological mechanisms of aging and develop interventions for age-related diseases and functional decline. Within the field of iPS cell research, interest has also grown beyond tissue regeneration through cell transplantation to include areas such as cellular rejuvenation, intercellular signaling, and improvement of the tissue environment, all of which may contribute to extending healthy lifespan.

I Peace’s business and research activities are centered around three key pillars:

1. Manufacturing clinical-grade and research-grade iPS cells for pharmaceutical companies and research institutions through the GMPeace service.
2. Providing personal iPS cell banking services to help individuals prepare for future medical advances through the My Peace service.
3. Conducting longevity-focused research and development based on iPS cell technologies.

Through this award, I Peace will continue to explore new possibilities for iPS cell technology while contributing to the extension of healthy lifespan worldwide and the advancement of the iPS cell manufacturing industry.

Note: iPSF is currently in the research and development stage and is not an approved pharmaceutical product intended to treat, prevent, or mitigate any specific disease.

About I Peace, Inc.

I Peace, Inc. is a biotechnology company pioneering the clinical and commercial application of induced pluripotent stem cell (iPSC) technologies for regenerative medicine and longevity. The company was founded in 2015 by Dr. Koji Tanabe, PhD, a leading expert in iPSC technology and an early pioneer of the field. Dr. Tanabe trained in Professor Shinya Yamanaka’s laboratory at Kyoto University and was the second author of the landmark research reporting the world’s first successful establishment of human iPS cells. This scientific heritage emphasizes I Peace’s commitment to advancing rigorous, high-quality iPSC science.

I Peace offers global services for individuals and enterprise partners, including personal iPSC banking from My Peace, as well as GMP‑compliant manufacturing, drug development, and global supply of clinical‑grade iPSCs from GMPeace. In parallel, the company is advancing the role of iPSC technology in the longevity and rejuvenation space through a strategic collaboration with Reju, Inc., highlighting the broad and transformative potential of iPSCs for improving human health. I Peace envisions a future where iPSC-derived therapies are readily available to everyone and where the use of iPSCs becomes a routine part of everyday healthcare. For more information, please visit https://ipeace.com/en/.

About My Peace

My Peace is a personal iPS cell banking service provided by I Peace, Inc. that helps individuals prepare for potential future regenerative medicines by developing and storing their own iPS cells. The process starts with a scheduled blood draw, followed by the clinical-grade manufacturing of the customer’s iPS cells. My Peace is supported by I Peace’s iPSC manufacturing expertise, offering customers their own personalized cell resource that can be used for future potential autologous therapeutics. For more information, visit https://mypeace-personal-ipscbanking.com/en/.

I Peace Media Contact
press@ipeaceinc.com

Ahead of Halloween, Zero Latency VR brought in “scientist of fear” Dr. Coltan Scrivner to explain why people can’t stop playing with the things that scare them

MELBOURNE, Australia, Oct. 2, 2026 /PRNewswire/ — Zero Latency VR, the world’s largest and most innovative immersive VR network, is celebrating a double Halloween anniversary: three years since the launch of Outbreak, its free-roam zombie survival shooter, and one year since the debut of Haunted, its immersive haunted house experience. Rather than mark the occasion alone, the company brought in an outside expert: Dr. Coltan Scrivner, a research scientist who studies why humans seek out frightening things for fun.

In three years, Outbreak has thrown wave after wave of the undead at guests across Zero Latency’s venues worldwide. In the year since, Haunted has barely let anyone make it through the lobby without a scream. Between the two, Halloween has become the company’s busiest and loudest season, leading Zero Latency to ask Scrivner a simple question: why do we pay money to be scared on purpose?

Scrivner is a research scientist at Arizona State University known for his work on morbid curiosity, horror, and what he calls “recreational fear”; the mixed feeling of fear and enjoyment that draws people to haunted houses, horror films, and survival games. He is the author of Morbidly Curious: A Scientist Explains Why We Can’t Look Away, and his research has been featured in The New York Times, CNN, The Economist, NPR and Scientific American.

“Humans are built to play with the things that frighten us,” said Scrivner. “It’s a great way for us to learn how to better regulate our fear and anxiety. One of the best ways to learn how you and your friends react in stressful situations is to simulate a stressful situation, and immersive VR is unmatched in its ability to safely invoke fear while maintaining a playful psychological frame.”

According to Scrivner, that’s exactly what sets free-roam VR apart from other horror formats. “The very best scary games blur the line between fiction and reality,” he said. “Immersive VR pushes that boundary and opens up a whole new way to play with fear. I have never experienced a horror game as immersive as Haunted or Outbreak, both of them were scarier, and more fun, than I could have imagined.”

“We’ve had over eleven years to perfect the jump scare, and it turns out you can’t fake it. The science backs it up,” said Tim Ruse, CEO of Zero Latency VR. “If you’re not leaving Outbreak with a slightly elevated heart rate, or leaving Haunted a little rattled, we haven’t done our job. It’s nice to finally have someone with a PhD confirm that’s a good thing.”

Zero Latency has two special Halloween double-features this spooky season; guests can experience Haunted and Undead Arena, the post-apocalyptic zombie shooter game show, or combine Outbreak with Outbreak 2: Mall Mayhem for a full hour of adrenaline-filled zombie survival that will truly get the blood pumping. Book now.

ABOUT ZERO LATENCY VR:

Zero Latency VR is the global pioneer in immersive entertainment, pushing the boundaries of what’s possible in location-based experiences. As the largest free-roam VR network on the planet, with 150+ cutting-edge venues across 34 countries, Zero Latency is where thrill-seekers come to live out their wildest fantasies.

SOCIAL MEDIA LINKS:

Instagram and TikTok: @zerolatencyvr

LinkedIn: Zero Latency VR

Press Contact:

Luke Mitchell

PR & Communications Manager

+61 (0) 413614412

luke.mitchell@zerolatencyvr.com

• Selected Mini PCs will be available at 20% to 35% off for a limited time on October 6–7

NEW YORK, Oct. 2, 2026 /PRNewswire/ — BOSGAME, a technology-based electronic product brand, will participate in Amazon Prime Big Deal Days 2026, offering limited-time savings on selected Mini PCs from October 6-7. Starting at 12:00 a.m. PDT on October 6, shoppers can save 20‑35% on list prices on featured models, offering a timely opportunity to upgrade their everyday computing setup for less.

As computers take on more tasks at home, consumers may prioritize different needs depending on how and where they use their devices. From home-office productivity and online learning to web browsing and media consumption, a compact PC can provide a practical computing option while taking up minimal desk space.

During Prime Big Deal Days, BOSGAME will feature four Mini PCs with different configurations to suit a range of everyday needs and budgets.

• BOSGAME E5: Powered by AMD Ryzen 5 5300U, the E5 handles everyday office work, web browsing and multitasking. Triple-display support and a compact, VESA-mountable design help maximize workspace in home offices or smaller desk setups.
• BOSGAME E5 Plus: Built for flexible home and office productivity, the E5 Plus combines AMD Ryzen 5 5400U performance with triple 4K display support. Upgradeable memory and expandable storage also leave room for evolving computing needs.
• BOSGAME E2 Plus: Designed for work, study and home use, the E2 Plus supports document editing, online meetings, learning and streaming. Its compact design and triple-display capability suit classrooms, home offices and other everyday spaces.
• BOSGAME E3 Neo: Powered by Intel N95, the E3 Neo offers a compact solution for essential home and office computing. Triple 4K display support and 2.5G LAN add flexibility for multi-screen setups and reliable wired connectivity.

The promotion runs through October 7, with savings of up to 35%, subject to product availability and Amazon’s promotional terms.

Whether upgrading a home-office setup, adding a computer for study, or choosing a compact device for browsing and entertainment, shoppers can explore BOSGAME’s featured Mini PCs during Amazon Prime Big Deal Days. For full promotion and product details, please visit the BOSGAME Amazon storefront at https://www.amazon.com/stores/BOSGAME/page/66639804-4D20-4901-A26F-0E6FE3715282.

Four new Ondo-designed portfolios join three powered by BlackRock, each combining multiple assets in a single onchain token with transparent holdings. 

TORTOLA, British Virgin Islands, Oct. 2, 2026 /PRNewswire/ — October 1, 2026 – Ondo Finance today announced four new Ondo-designed portfolios, expanding Ondo Intelligent Portfolios to seven offerings. The new portfolios join the three initial portfolios powered by BlackRock and give non-US investors onchain access to some of the markets most closely watched themes, from big tech and artificial intelligence to income. 

This expanded lineup includes MAG7Xon, which pairs the Magnificent 7 with crypto; BRAINon, a portfolio of AI leaders, YLD5on, which targets 5% income; and YLD8on which targets 8% income. Each portfolio combines multiple assets in a single onchain token, with transparent holdings and pragmatic rebalancing. Investors get diversified exposure in one position. 

This expansion marks an early step in a generational shift in how the world invests. It brings more institutional asset allocation expertise onchain and expands who can access it. All seven portfolios are available today to eligible investors on Ethereum and BNB Chain through leading wallets, exchanges and DeFI apps. 

This product line will continue to expand, with additional onchain portfolios over time. 

About Ondo Finance
Ondo Finance is a blockchain-based platform focused on tokenizing real-world assets and bringing institutional-quality financial products onchain. By bridging traditional finance and decentralized infrastructure, Ondo aims to make capital markets more accessible, transparent, and efficient.

About Ondo Global Markets
Ondo Global Markets is an issuance and redemption platform for tokenized publicly traded U.S. stocks and ETFs. It enables investors outside the United States to gain economic exposure to these assets by minting, transferring, and redeeming securities-backed tokens. Each token is fully backed by the corresponding stock or ETF (together with cash in transit).